Categories
Business Coronavirus Featured Headlines News

Warm Autoimmune Hemolytic Anemia (WAIHA) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030

Autoantibodies are antibodies that react with self-antigens. They are produced by both tissue and circulating self-reactive B lymphocytes, following cooperation with T helper lymphocytes. Autoimmune hemolytic anemia (AIHA) is defined as the increased destruction of red blood cells (RBCs) in the presence of anti-RBC autoantibodies with or without complement activation.

WAIHA is the most common type of autoimmune hemolytic anemia, comprising ∼70–80% of all adult cases and ∼50% of the pediatric cases. More than half of these cases are called primary due to undefined etiology. At the same time, the rest is termed a secondary to lymphoproliferative syndromes, malignant diseases, including chronic lymphoblastic leukemia (CLL), non-Hodgkin’s lymphoma, and solid tumors.

The present mainstay of therapies include Corticosteroids, Intravenous immunoglobulin (IVIG), Danazol, Rituximab, Splenectomy, Immunosuppressive drugs, and lastly, hematopoietic stem cell transplantation (HSCT). Currently there are no approved therapies for the management of WAIHA with only one-third of the patients maintaining sustained disease control once steroids are discontinued.

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/warm-auoimmune-hemolytic-anemia-waiha-epidemiology-insights

warm-auoimmune-hemolytic-anemia-waiha-epidemiology-insights
Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology

DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The DelveInsight Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology report gives a thorough understanding of the Warm Autoimmune Hemolytic Anemia (WAIHA) disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Warm Autoimmune Hemolytic Anemia (WAIHA) in the US, Europe, and Japan. The report covers the detailed information of the Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology scenario in seven major countries (US, EU5, and Japan).

Key Highlights Of The Report

The total prevalent population of Warm Autoimmune Hemolytic Anemia (WAIHA) in the 7MM was 82,045 in 2017. Estimates show that Secondary WAIHA comprises a higher number of cases as compared to Primary WAIHA cases.

According to DelveInsight’s analysis, females are affected more as compared to males in the case of warm autoimmune hemolytic anemia (WAIHA).

Warm autoimmune hemolytic anemia (WAIHA) tends to affect adults more than children and adolescents in seven major markets.

Among the European 5 countries, Germany had the highest prevalent population of WAIHA, followed by France. On the other hand, Spain had the lowest prevalent population in 2017.

Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology

  • Delveinsight’s Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. 
  • The Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. 
  • The Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. 
  • It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Scope of the Report

  • The report provides insight into the historical and forecasted patient pool of Warm Autoimmune Hemolytic Anemia (WAIHA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Warm Autoimmune Hemolytic Anemia (WAIHA).
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The Warm Autoimmune Hemolytic Anemia (WAIHA) report provides a detailed overview explaining Warm Autoimmune Hemolytic Anemia (WAIHA) causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology Report and Model provide an overview of the risk factors and global trends of Warm Autoimmune Hemolytic Anemia (WAIHA) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides the segmentation of the Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology. 

Key Benefit of Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology Report 

The Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Warm Autoimmune Hemolytic Anemia (WAIHA) market
  • Quantify patient populations in the global Warm Autoimmune Hemolytic Anemia (WAIHA) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Warm Autoimmune Hemolytic Anemia (WAIHA) therapeutics in each of the markets covered
  • Understand the magnitude of Warm Autoimmune Hemolytic Anemia (WAIHA) population by its epidemiology
  • The Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/warm-auoimmune-hemolytic-anemia-waiha-epidemiology-insights

Table of Contents

  1. Key Insights 
  2. Executive Summary of Warm Autoimmune Hemolytic Anemia (WAIHA)
  3. Warm Autoimmune Hemolytic Anemia (WAIHA) Disease Background and Overview
  4. Warm Autoimmune Hemolytic Anemia (WAIHA) Patient Journey
  5. Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology and Patient Population
  6. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Algorithm, Current Treatment, and Medical Practices
  7. KOL Views on Warm Autoimmune Hemolytic Anemia (WAIHA) 
  8. Warm Autoimmune Hemolytic Anemia (WAIHA) Unmet Needs
  9. Appendix
  10. DelveInsight Capabilities
  11. Disclaimer
    *The table of contents is not exhaustive; will be provided in the final report

Related Reports
Warm Autoimmune Hemolytic Anemia (WAIHA) Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (WAIHA) – Market Insights, Epidemiology and Market Forecast-2030′ report delivers an in-depth understanding of the disease,historical and forecasted epidemiology as well as the market trends of WAIHAs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us
Shruti Thakur
[email protected]
+91-9650213330
https://www.delveinsight.com/
LinkedIn | Facebook | Twitter
Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology Report
https://www.delveinsight.com/sample-request/warm-auoimmune-hemolytic-anemia-waiha-epidemiology-insights